EyePoint Pharmaceuticals Inc
announced interim masked safety data for its lead product candidate EYP-1901 from its ongoing Phase 2 PAVIA trial of EYP-1901 as a potential nine-month treatment for moderately severe to severe non-proliferative diabetic retinopathy and DAVIO 2 trial as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration.
All treatment arms in the PAVIA trial have reached at least three months post-dosing follow-up as of September 1, 2023.
Approximately 170 patients have received EYP-1901 with a minimum of three months of follow-up post-injection from the ongoing Phase 2 PAVIA and DAVIO 2 trials and the completed DAVIO 1 trial with no reported drug-related ocular severe adverse events (SAEs) and no reported drug-related systemic SAEs.
In the PAVIA clinical trial, there have been no reported drug-related ocular SAEs and drug-related systemic SAEs. There were two ocular SAEs deemed unrelated to EYP-1901 by investigators:
- Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight weeks after dosing
- Macular edema leading to vision loss in the non-study fellow eye
The company remains on track to share topline results from the DAVIO 2 trial in December of this year and the PAVIA trial in the second quarter of 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.